Multicenter Two-Part Study Presented at 2012 Gastrointestinal Cancers Symposium
SAN FRANCISCO, Jan 20, 2012 (GlobeNewswire via COMTEX) --
Immunomedics, Inc.
/quotes/zigman/73672/quotes/nls/immu IMMU
-3.63%
, a biopharmaceutical company primarily focused on the development of
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases, today announced that repeated
cycles of fractionated doses of its proprietary humanized antibody,
clivatuzumab tetraxetan, labeled with yttrium-90 (90Y) and given in
combination with gemcitabine, demonstrated therapeutic activity in
patients with advanced, inoperable, pancreatic cancer.
A total of 100 patients with previously untreated Stage III or IV
pancreatic cancer were enrolled into this open-label trial to receive
gemcitabine once-weekly x 4 with 90Y-clivatuzumab tetraxetan on weeks 2,
3 and 4 (therapy cycle). The therapy cycle could be repeated until
disease progression or patient displayed unacceptable toxicity. Ten
patients withdrew early, while 90 patients, of whom 82 had the Stage IV
(metastatic) disease, received 1 -- 4 therapy cycles.
In Part I of this study, 38 patients were treated with 90Y-clivatuzumab
tetraxetan at 6.5, 9, 12 or 15 mCi/m2 x 3, and a low, fixed gemcitabine
dose of 200 mg/m2 x 4 for radiosensitization. Thirteen patients were
retreated with the same cycle 1 - 3 times. The overall disease control
rate, which includes complete response (CR), partial response (PR) and
stable disease (SD), by CT-based RECIST criteria, was 58%, including 6
patients (16%) with PR and 16 patients (42%) with SD as best response.
The median overall survival (OS) for the 38 treated patients was 7.7
months, which compares favorably with other regimens for advanced
pancreatic cancer. At the higher therapy doses (12 and 15 mCi/m2 of
90Y-clivatuzumab tetraxetan x 3), a median OS of 8.0 months was noted.
For the 13 patients who received repeated cycles of the combination
therapy, median OS improved to 11.8 months. (For more information,
please refer to the Company's press release at
www.immunomedics.com/pdfs/news/2011/PR06072011.pdf ).
Fifty-two patients were treated in Part II of this study to receive 3
weekly 90Y doses of 12 mCi/m2 and gemcitabine doses of 200, 600 or 1000
mg/m2 x 4, with 14 patients receiving repeated therapy cycles at the
same gemcitabine dose but 90Y doses of 6.5, 9 or 12 mCi/m2. Results from
47 patients were reported at the Symposium. The disease control rate
for the 200 mg/m2 group was 72%, with 19% PR and 53% SD. For the 600 and
1000 mg/m2 groups, the disease control rates were 63% (0% PR) and 68%
(18% PR), respectively. Higher gemcitabine doses appeared to offer no
advantage in treatment response over the lowest dose of 200 mg/m2. At
the time of reporting, survival data were not available for this group
of patients.
"These results from Part II of this clinical trial continue to support
the use of antibody-directed radiation therapy with 90Y-clivatuzumab
tetraxetan in patients with late-stage pancreatic cancer," remarked
Cynthia L. Sullivan, President and Chief Executive Officer. "We are in
discussions with FDA and opinion leaders regarding further development
and eventual registration of this novel therapy modality," Ms. Sullivan
added.
Treatments were well tolerated with no infusion reactions to
radiolabeled clivatuzumab and few non-hematologic side effects.
Hematologic suppression was transient after cycles 1 and 2.
About Clivatuzumab Tetraxetan
Clivatuzumab tetraxetan is a humanized monoclonal antibody targeting a
mucin antigen expressed in most pancreatic cancers, but not
pancreatitis, normal pancreas or most other normal tissues. Preclinical
studies in mice with human pancreatic cancer xenografts given the
murine version of 90Y-clivatuzumab tetraxetan demonstrated favorable
tumor responses, which could be further improved when given in
combination with gemcitabine. A prior Phase I single dose-escalation
study of 90Y-clivatuzumab tetraxetan in treatment-relapsed pancreatic
cancer patients has also produced encouraging results, with evidence of
objective responses. The radiolabeled humanized antibody recently
completed a Phase Ib/II fractionated dose-escalation study in
combination with gemcitabine for the treatment of patients with newly
diagnosed, untreated, Stage III or Stage IV cancer of the pancreas.
About Pancreatic Cancer
According to the American Cancer Society, pancreatic cancer is the
fourth leading cause of cancer death for both sexes in the United
States. The death rate for pancreatic cancer increased by 0.4% per year
from 2004 to 2008, despite a reduction in overall cancer death rates
since 1990. In 2012, an estimated 37,390 Americans are expected to die
from the disease. With about 43,920 new cases in 2012, incidence rates
of pancreatic cancer are also on the rise, increasing by 1.5% per year
since 2004. For patients with advanced cancers, the median survival is
5.65 months. The overall 1-and 5-year relative survival rates for all
stages are 26% and 6%, respectively. Currently, the standard therapy for
pancreatic cancer is gemcitabine, alone or in combination with other
chemotherapeutics.
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily
focused on the development of monoclonal antibody-based products for the
targeted treatment of cancer, autoimmune and other serious diseases. We
have developed a number of advanced proprietary technologies that allow
us to create humanized antibodies that can be used either alone in
unlabeled or "naked" form, or conjugated with radioactive isotopes,
chemotherapeutics, cytokines or toxins, in each case to create highly
targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms
of action. We also have a majority ownership in IBC Pharmaceuticals,
Inc., which is developing a novel Dock-and-Lock (DNL) methodology with
us for making fusion proteins and multifunctional antibodies, and a new
method of delivering imaging and therapeutic agents selectively to
disease, especially different solid cancers (colorectal, lung, pancreas,
etc.), by proprietary, antibody-based, pretargeting methods. We believe
that our portfolio of intellectual property, which includes
approximately 189 patents issued in the United States and more than 400
foreign patents, protects our product candidates and technologies. For
additional information on us, please visit our website at
www.immunomedics.com . The information on our website does not,
however, form a part of this press release.
This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities
Litigation Reform Act of 1995. Such statements, including statements
regarding clinical trials, out-licensing arrangements (including the
timing and amount of contingent payments), forecasts of future operating
results, potential collaborations, and capital raising activities,
involve significant risks and uncertainties and actual results could
differ materially from those expressed or implied herein. Factors that
could cause such differences include, but are not limited to, risks
associated with any cash payment that the Company might receive in
connection with a sublicense involving a third party and UCB, which is
not within the Company's control, new product development (including
clinical trials outcome and regulatory requirements/actions), our
dependence on our licensing partners for the further development of
epratuzumab for autoimmune indications and veltuzumab for non-cancer
indications, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at
all, as well as the risks discussed in the Company's filings with the
Securities and Exchange Commission. The Company is not under any
obligation, and the Company expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result of
new information, future events or otherwise.
This news release was distributed by GlobeNewswire,
www.globenewswire.com
SOURCE: Immunomedics, Inc.
No comments:
Post a Comment